Evidence map›Paper›PMID 39844686›Full record

ArticleImmunotherapy2025

Survival impact of immune-related adverse events in extensive stage small cell lung cancer patients: a retrospective cohort study.

John C Hunting, Sarah N Price, Andrew T Faucheux, Eric Olson, Catherine A Elko, Alexander Quattlebaum, Jimmy Ruiz, Thomas William Lycan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

John C HuntingDepartment of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA.ORCID 0000-0002-4066-4763
Sarah N PriceDepartment of Social Sciences and Health Policy, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Andrew T FaucheuxDepartment of Hematology & Oncology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Eric OlsonDepartment of Hematology & Oncology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Catherine A ElkoDepartment of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Alexander QuattlebaumDepartment of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Jimmy RuizDepartment of Hematology & Oncology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Thomas William LycanDepartment of Hematology & Oncology, Wake Forest School of Medicine, Winston-Salem, NC, USA.

Funding

CTSA K12 Program at Wake ForestK12TR004931 · NCATS · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Nicholette D. Allred · 2024 to 2026
$2.3M
Cancer Prevention And Control Training Grant (CAPACITY)T32CA122061 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI KRISTIE L FOLEY, Kathryn Elizabeth Weaver · 2019 to 2026
$2.1M
NCATS NIH HHS K12 TR004931NCI NIH HHS T32 CA122061
6 · The paper itself

Abstract

backgroundPrior research indicates a connection between immune-related adverse events (irAEs) and improved progression-free survival (PFS) and overall survival (OS) in non-small cell lung cancer. However, limited data exists for extensive stage small cell lung cancer (ES-SCLC).

methodsThis study included all ES-SCLC patients who received at least one dose of an immune checkpoint inhibitor between 2 January 2011 and 4 July 2022 using a large retrospective registry from a single institution. PFS and OS were right-censored at the date of last follow-up and were estimated using the Kaplan-Meier method. Differences in PFS and OS between irAE groups were assessed using Cox proportional hazards models.

resultsAmong 245 patients with ES-SCLC; 56 (23%) experienced irAEs, 24 (42.9%) of which were high-grade (3-4). High-grade irAEs occurred at a median of 1.2 months (interquartile range [IQR] 0.45-2.5), while low-grade irAE occurred at 2.8 months (1.3-5.2). PFS was significantly longer among any irAE vs none (HR = 0.49; [95%CI 0.32-0.77]) as was OS (HR = 0.49; [95%CI 0.34-0.72]).

conclusionsIn ES-SCLC patients treated with immunotherapy, those who experienced any irAE demonstrated a two-fold increase in both PFS and OS compared to those without an irAE. This is consistent with other tumor primaries.

Indexed as

Drug-Related Side Effects and Adverse ReactionsImmune Checkpoint InhibitorsImmunotherapyLung NeoplasmsSmall Cell Lung CarcinomaAgedAged, 80 and overFemaleHumansMaleMiddle AgedNeoplasm StagingRetrospective StudiesImmune Checkpoint Inhibitorsadverse eventsextensive stage small cell lung cancerImmunotherapyoutcomessurvival

Identifiers

PMID39844686
PMCPMC11834449

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.